Compare SNBR & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNBR | ATOS |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4M | 36.2M |
| IPO Year | 1998 | 2010 |
| Metric | SNBR | ATOS |
|---|---|---|
| Price | $0.72 | $4.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.50 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 18.1M | 41.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,411,450,000.00 | $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.96 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $0.53 |
| 52 Week High | $13.94 | $7.56 |
| Indicator | SNBR | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 32.51 | 34.83 |
| Support Level | N/A | $3.80 |
| Resistance Level | $1.91 | $6.18 |
| Average True Range (ATR) | 0.28 | 0.27 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 23.79 | 3.57 |
Sleep Number Corp is a designer, manufacturer, marketer, and retailer, which allows it to offer consumers high-quality, individualized sleep solutions and services. It also offers FlextFit adjustable bases, and Sleep Number pillows, sheets, and other bedding products. The company generates revenue by marketing its innovations directly to new and existing customers and selling products through its Stores, Online, Phone, Chat (Total Retail), and Other. It focuses on personalized sleep wellness, with mattresses designed to evolve with each sleeper to help them feel and perform well, featuring adjustable firmness, pressure-relieving support, and temperature-balancing comfort built into every mattress. Its products include mattresses, bundles, bedding, pillows, and furniture.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.